Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease

Jieun Kang, Dae Hyun Jeong, Minkyu Han, Suk-Kyun Yang, Jeong-Sik Byeon, Byong Duk Ye, Sang Hyoung Park, Sung Wook Hwang, Tae Sun Shim, and Kyung-Wook Jo

Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, Seoul, Korea
Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

ABSTRACT

Background: We investigated the incidence of active tuberculosis among patients with inflammatory bowel disease (IBD) treated with tumor necrosis factor (TNF) inhibitors, with or without latent tuberculosis infection (LTBI).

Methods: The study was performed at a Korean tertiary referral center between January 2011 and June 2017. In total, 740 patients with IBD who underwent LTBI screening tests and were followed-up for ≥ 1 year after TNF inhibitor treatment initiation were enrolled. LTBI was detected on the basis of tuberculin skin test results, interferon-gamma release assay results, chest X-ray findings, and previous tuberculosis treatment history. The patients were classified into LTBI (n = 84) or non-LTBI (n = 656) group. The risk of developing tuberculosis in each group was assessed on the basis of standardized incidence ratio (SIR) and 95% confidence interval (CI) for active tuberculosis.

Results: Mean patient age was 33.1 years, and patients with Crohn’s disease were predominant (80.7%). Within 1 year after the initiation of TNF inhibitor treatment, 1 patient in the LTBI group (1/84; 1.2%) and 7 patients in the non-LTBI group (7/656; 1.1%) developed active tuberculosis. The overall 1-year incidence of tuberculosis among the patients was significantly higher than that among the general population (SIR, 14.0; 95% CI, 7.0–28.0), and SIR was not affected by LTBI status (LTBI group: 14.5, 95% CI, 2.0–102.6; non-LTBI group: 14.0, 95% CI, 6.7–29.4).

Conclusion: Patients with IBD undergoing TNF inhibitor treatment showed a higher 1-year incidence of tuberculosis than the general population irrespective of LTBI status.

Keywords: Tuberculosis; Inflammatory Bowel Disease; TNF Inhibitor
INTRODUCTION

Tumor necrosis factor (TNF) inhibitors have been increasingly used to treat immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel disease (IBD). However, patients treated with TNF inhibitors are at an increased risk of developing tuberculosis including extrapulmonary tuberculosis\(^1\) because of the reactivation of latent tuberculosis infection (LTBI).\(^2\) These findings have led to the implementation of policies to diagnose LTBI prior to the initiation of TNF inhibitor treatment.\(^3,4\)

Current diagnostic tests for LTBI include tuberculin skin tests (TST) and interferon-gamma release assay (IGRA). Additionally, to determine LTBI treatment, other factors, such as chest X-ray screening, physical examination, medical history including previous tuberculosis treatments and their adequacy, and the history of recent contact with patients with active tuberculosis, are considered.\(^2\) The widespread screening and treatment of LTBI prior to TNF inhibitor treatment have dramatically reduced the incidence of tuberculosis.\(^5\) However, previous studies have reported several cases of patients with IMID who developed tuberculosis associated with TNF inhibitor use, despite negative LTBI screening results.\(^6-9\) Moreover, some studies have reported the development of active tuberculosis in patients with IMID who received appropriate LTBI treatment prior to the initiation of TNF inhibitors.\(^6,9\) These reports suggest that although appropriate LTBI test and subsequent treatment prior to TNF inhibitor treatment can reduce the incidence of tuberculosis in patients with IMID, tuberculosis can still develop in patients with negative LTBI results as well as those receiving adequate LTBI treatment. To our knowledge, no study has been conducted that focuses upon the incidence of active tuberculosis in patients with IBD with different LTBI statuses who are undergoing TNF inhibitor treatment. Therefore, this study investigated this issue in Korea, where the incidence of tuberculosis is considered to be intermediate (80–100/100,000 per year).\(^10\)

METHODS

Study subjects

This retrospective cohort study was performed between January 2011 and June 2017, with 740 patients with IBD, including cases of Crohn’s disease and ulcerative colitis. All patients underwent TNF inhibitor treatment and were followed-up for ≥ 1 at Asan Medical Center, a 2,700-bed tertiary care center in Korea. The enrolled patients were selected from among 895 patients after applying the following exclusion criteria: 1) patient was followed-up for < 1 year, 2) patient did not undergo LTBI screening test, or 3) patient was diagnosed as having active tuberculosis at the screening visit (Fig. 1). Medical records of the remaining patients were retrospectively analyzed in August 2017.

LTBI screening strategy

During the screening visit, information was registered according to LTBI Status after TNF Inhibitor

TST and/or IGRA were performed on the same day during the baseline examination. TST was performed with
Tuberculosis according to LTBI Status after TNF Inhibitor

Patients with IBD who received TNF treatment between January 2011 and June 2017 (n = 895)

Excluded (n = 155)
- Follow up of < 1 yr (n = 138)
- Did not undergo LTBI test (n = 14)
- Active TB diagnosed (n = 3)

IBD patients who underwent LTBI test and were followed-up for ≥ 1 yr (n = 740)

LTBI group (n = 84)
- Development of active TB (n = 2)
  - TB development after 1 yr (n = 1, at 33 mon)
  - Active TB development within 1 yr (n = 1)

Non-LTBI group (n = 656)
- Development of active TB (n = 12)
  - TB development after 1 yr (n = 5, at 14, 17, 24, 27, and 55 mon)
  - Active TB development within 1 yr (n = 7)

**Fig. 1. Study flow chart.**

IBD = inflammatory bowel disease, TNF = tumor necrosis factor, LTBI = latent tuberculosis infection, TB = tuberculosis.

2TU PPD RT23 (Statens Serum Institute, Copenhagen, Denmark), following the Mantoux approach. Induration size was measured after 48–72 hours through the ballpoint method, and an induration ≥ 10 mm was defined as positive, as indicated in the Korean Tuberculosis Guidelines. In addition, IGRA was performed using the QuantiFERON-TB Gold In-Tube (QFT-GIT; Cellestis, Carnegie, VIC, Australia), according to the manufacturer's instructions. An interferon-γ value of ≥ 0.35 IU/mL was considered as a positive QFT-GIT result. LTBI was considered positive if either the TST or QFT-GIT result was positive.

**Criteria for LTBI treatment and its regimen**

LTBI treatment was initiated in patients with positive results, normal chest radiography, and the absence of tuberculosis-suggestive symptoms. Moreover, patients with a positive TST and/or QFT-GIT result, a history of previous adequate anti-tuberculosis treatment, and no further tuberculosis exposure were not treated for LTBI. Patients with no previous anti-tuberculosis treatment history and presenting with chest X-ray abnormalities suggestive of spontaneously healed tuberculosis (e.g., non-calcified nodules with distinct margins, discrete linear or reticular fibrotic scars, and fibrotic linear opacity) received LTBI treatment regardless of TST or QFT-GIT results. TNF inhibitor was initiated at 4 weeks after LTBI treatment.

During the study period, the primary selected regimen for LTBI treatment was a combination of isoniazid and rifampin administered for 3 months. In the case of adverse events or intolerance to the treatment, a new regimen was used, comprising either isoniazid for 9 months or rifampin for 4 months. Treatment completion required completing > 80% of all prescribed medication within 4 months for isoniazid/rifampin combination, 12 months for isoniazid, and 6 months for rifampin.
Follow-up and development of active tuberculosis

Regardless of the LTBI status, the patients were followed-up by pulmonologists until 6 months after the completion of the TNF inhibitor treatment. Chest X-ray screening was performed at 3 and 9 months after treatment initiation, and at every 12 months thereafter to detect cases of active tuberculosis. The patients were instructed to visit their physicians if they presented any new symptoms or signs suggestive of tuberculosis. For the present study, only the cases where active tuberculosis developed within 1 year of treatment initiation were considered to be treatment-related because the risk of developing tuberculosis due to the reactivation of LTBI is highest within 1 year after the initiation of TNF inhibitor treatment.\textsuperscript{14,15}

Statistical analysis

Results are presented as means and standard deviations for continuous variables and numbers and percentages for categorical variables. The risk of developing tuberculosis was assessed on the basis of the standardized incidence ratio (SIR) and its 95% confidence interval (CI) for active tuberculosis. The observed number of tuberculosis cases was divided by the expected number of tuberculosis cases for each 10-year age- and sex-stratified general population in Korea. The expected number of tuberculosis cases was estimated on the basis of the incidence of active tuberculosis in the entire population in 2014, which was the midpoint of the study period, provided by the Korean Centers for Disease Control and Prevention.\textsuperscript{16} In addition, for patients diagnosed with active tuberculosis within 1 year, the number of person-years at risk (pyr) was calculated from the date of initiation of TNF inhibitor treatment until the date of tuberculosis diagnosis. Continuous variables were analyzed with a Student’s t-test, whereas categorical variables were analyzed with either \( \chi^2 \) or Fisher’s exact test. All tests were two-sided, and a \( P \) value < 0.05 was considered as statistically significant. All analyses were performed using the SPSS software (version 21.0; SPSS, Chicago, IL, USA).

Ethics statement

The study protocol was approved by the Institutional Review Board (IRB) of Asan Medical Center (IRB No. 2017-0014), which waived the requirement of informed consent because of the retrospective nature of the analysis.

RESULTS

Clinical characteristics of study patients

Following the application of eligibility criteria, a total of 740 patients with IBD who received TNF inhibitor treatment were enrolled (Fig. 1). Mean patients age was 33.1 \( \pm \) 12.0 years, and 65.8\% (487/740) of the patients were male. Patients with Crohn’s disease were predominant (80.7\%). During the study period, 3 types of TNF inhibitors were administered: infliximab (prescribed to 68.5\% of the cases), adalimumab (prescribed to 30.7\% of the cases), and golimumab (prescribed to 0.8\% of the cases). Azathioprine was the most frequently used anti-inflammatory agent. A detailed description of the cases is presented in Table 1.

Diagnosis and treatment of LTBI

As shown in Fig. 1, 84 among 740 patients (11.4\%) presented with LTBI (LTBI group). Among those, 49 (58.3\%) showed negative TST and positive QFT-GIT results, whereas 18 (21.4\%) showed positive results for both TST and QFT-GIT, 16 (19.0\%) showed a positive TST and a negative or indeterminate QFT-GIT result, and 1 patient (1.2\%) presented chest X-ray.
findings suggestive of spontaneously healed tuberculosis, with no history of tuberculosis treatment. Among the 84 patients, 72 (85.7%) completed LTBI treatment with isoniazid/ rifampin combination for 3 months, whereas the 12 remaining patients underwent regimen changes due to intolerance and adverse events. From those 12 patients, 9 completed LTBI treatment with the new regimen, resulting in an overall completion rate of 96.4% (81/84) of LTBI group. The remaining 3 patients did not complete LTBI treatment due to various adverse events, such as nausea with vomiting.

Meanwhile, the remaining 656 patients classified as non-LTBI group, 645 (98.3%) showed negative results for both TST and QFT-GIT, whereas 11 (1.7%) showed an adequate treatment history of tuberculosis and positive results for TST and/or QFT-GIT. As shown in Table 1, the two groups differed in several baseline characteristics, such as age, sex, body mass index, type of IBD, TNF inhibitor used, and anti-inflammatory drugs administered.

### Development of tuberculosis within 1 year according to the LTBI status and treatment

During the follow-up period, 14 cases of active tuberculosis occurred (Fig. 1), from which 6 were excluded due to being diagnosed more than 1 year after treatment initiation. The remaining 8 cases were included in the analysis. As shown in Fig. 1, 1 patient in the LTBI group (1/84; 1.2%) and 7 patients in the non-LTBI group (7/656; 1.1%) developed active tuberculosis within 1 year after the initiation of TNF inhibitor treatment. Detailed characteristics of these 8 patients are presented in Table 2.

**Table 1. Clinical characteristics of 740 patients with IBD treated with TNF inhibitor according to the LTBI status**

| Characteristics                                      | Total (n = 740) | LTBI group (n = 84) | Non-LTBI group (n = 656) | P value |
|------------------------------------------------------|----------------|--------------------|--------------------------|---------|
| Age, yr                                              | 33.1 ± 12.0    | 39.4 ± 13.9        | 32.3 ± 11.47             | < 0.001 |
| Sex, male                                            | 487 (65.8)     | 67 (79.8)          | 420 (64.0)               | 0.004   |
| BMI, kg/m²                                           | 20.2 ± 3.3     | 21.3 ± 3.2         | 20.0 ± 3.3               | 0.001   |
| Type of IBD                                          |               |                    |                          |         |
| Crohn's disease                                      | 597 (80.7)     | 55 (65.5)          | 542 (82.6)               | < 0.001 |
| Ulcerative colitis                                   | 143 (19.3)     | 29 (34.5)          | 114 (17.4)               |         |
| Comorbid conditions                                  |               |                    |                          |         |
| Chronic liver disease                                | 14 (1.9)       | 2 (2.4)            | 12 (1.8)                 | 0.667   |
| Hypertension                                         | 12 (1.6)       | 3 (3.6)            | 9 (1.4)                  | 0.146   |
| Chronic lung disease                                 | 5 (0.7)        | 1 (1.2)            | 4 (0.6)                  | 0.453   |
| Diabetes mellitus                                    | 3 (0.4)        | 1 (1.2)            | 2 (0.3)                  | 0.304   |
| Chronic renal disease                                | 2 (0.3)        | 0 (0.0)            | 2 (0.3)                  | > 0.999 |
| History of TB                                        | 29 (3.9)       | 1 (1.2)            | 28 (4.3)                 | 0.237   |
| Positive BCG scar                                    | 456 (61.6)     | 56 (66.7)          | 400 (61.0)               | 0.313   |
| CXR findings suggestive of healed TB                 | 31 (4.2)       | 7 (8.3)            | 24 (3.7)                 | 0.073   |
| TNF inhibitors used                                   |               |                    |                          | 0.868   |
| Infliximab                                           | 507 (68.5)     | 56 (66.7)          | 451 (68.8)               |         |
| Adalimumab                                           | 227 (30.7)     | 27 (32.1)          | 200 (30.5)               |         |
| Golimumab                                            | 6 (0.8)        | 1 (1.2)            | 5 (0.8)                  |         |
| Sequential treatment of TNF inhibitors*              | 29 (3.9)       | 7 (8.3)            | 22 (3.4)                 | 0.037   |
| Anti-inflammatory drugs                               |               |                    |                          |         |
| Azathioprine                                         | 353 (47.7)     | 40 (47.6)          | 313 (47.7)               | 0.987   |
| Steroid                                              | 73 (9.9)       | 12 (14.3)          | 61 (9.3)                 | 0.149   |
| Others*                                              | 183 (24.7)     | 29 (34.5)          | 154 (23.5)               | 0.027   |
| None                                                 | 207 (28.0)     | 13 (15.5)          | 194 (29.6)               | 0.007   |

Data are reported as mean ± standard deviations or number (%).

IBD = inflammatory bowel disease, TNF = tumor necrosis factor, LTBI = latent tuberculosis infection, BMI = body mass index, TB = tuberculosis, BCG = bacillus Calmette–Guérin, CXR = chest radiography.

*Switch of TNF inhibitors: infliximab to adalimumab in 23 patients, adalimumab to infliximab in 4 patients, infliximab to adalimumab in 1 patient, and golimumab to infliximab in 1 patient; Others include methotrexate, 6-mercaptopurine, and sulfasalazine.
Incidence of 1-year tuberculosis according to the LTBI status and in relation to the general population

Table 3 shows the observed number of tuberculosis cases and SIRs of all patients (both LTBI and non-LTBI group). The overall incidence of 1-year tuberculosis adjusted for sex and age, was significantly higher among the study patients than in the general population (SIR, 14.0; 95% CI, 7.0–28.0), and there was no significant effect of the LTBI status on SIR (LTBI group: 14.0, 95% CI, 2.0–99.0, non-LTBI group: 14.0, 95% CI, 6.7–29.4). Fig. 2 shows incidence rates of active tuberculosis per 100,000 pyr after the initiation of TNF inhibitor treatment in patients with IBD. Average tuberculosis incidences among IBD patients were 1,276.8 per 100,000 pyr (95% CI, 638.5–2,553.2) overall, 1,270.5 per 100,000 pyr (95% CI, 179.0–9,019.7) for the LTBI group, and 1,277.7 per 100,000 pyr (95% CI, 609.1–2,680.2) for the non-LTBI group.
DISCUSSION

The use of TNF inhibitors has been validated as a suitable treatment for IBD. However, a small number of patients with IBD have been known to develop treatment-related tuberculosis even after screening and adequate treatment for LTBI. To the best of our knowledge, this was the first study to compare the incidence of active tuberculosis in patients with IBD with different LTBI status within 1 year after the initiation of TNF inhibitor treatment. We showed that the incidence of active treatment-related tuberculosis among patients with IBD was 14 times higher than that in the general population even after LTBI screening was performed and adequate treatment was administered. Notably, this high incidence was not significantly affected by the LTBI status of the patients.

We considered the development of tuberculosis to be related to TNF inhibitor therapy only if it was diagnosed within 1 year of treatment initiation because the risk of LTBI reactivation is the highest during the first 6–12 months of TNF inhibitor treatment. A previous study has reported a biphasic development of active tuberculosis disease during long-term TNF inhibitor treatment in patients with rheumatoid arthritis, with an early development occurring within the first 3 months and a late development after 20–24 months of therapy. Active tuberculosis disease could be caused by LTBI reactivation in those with an early development of tuberculosis and by de novo infection in those with the baseline negative LTBI results and a late development of tuberculosis. In previous studies analyzing the development of active tuberculosis in patients with IMID, including those with IBD, all cases were included regardless of time period following TNF inhibitor treatment. In the present study, we analyzed only the cases that developed tuberculosis within 1 year of treatment initiation since the baseline LTBI screening prior to the use of TNF inhibitors prevents the early development of active tuberculosis and theoretically cannot prevent its late development. To our knowledge, this was the first study to analyze the incidence of active tuberculosis in IBD patients treated with TNF inhibitors, wherein late tuberculosis development was excluded.

In the present study, 1 patient within the LTBI group (No 1. in Table 2), who had been treated for LTBI, was diagnosed with active tuberculosis. The most plausible explanation was that anti-tuberculosis chemoprophylaxis is only partially successful in patients with IMID. In a study performed in Greece with 613 enrolled patients of rheumatic diseases who had received TNF inhibitor treatment, 45 patients received chemoprophylaxis for LTBI treatment, and 6 of those patients developed active tuberculosis within 1 year after the initiation of TNF inhibitor treatment. Similar observations have been reported by other authors, and a recent study conducted in the Netherlands has reported that the estimated reduction in the risk of active tuberculosis following preventive treatment among LTBI patients ranged between 40% and 60%. Taken together, these findings suggest that although the screening and treatment of LTBI prior to TNF inhibitor can dramatically reduce the incidence of tuberculosis, complete prevention may not be achievable. Another possible explanation is that patients develop tuberculosis due to a new infection with Mycobacterium tuberculosis even within relatively short periods. Immunocompromised condition attributable to TNF inhibitor treatment makes these patients susceptible to active tuberculosis. While our patients' histories were not suggestive of exposure to other infectious patients, living in a tuberculosis-prevalent country such as Korea makes inadvertent exposure plausible.
Among the 656 patients of non-LTBI group, 7 patients developed active tuberculosis despite a negative LTBI result or a history of previous adequate tuberculosis treatment. It was probable that the development of tuberculosis in these patients was due to the incomplete sensitivity of LTBI tests, including TST and/or IGRA. That is, TST and IGRA can provide false-negative results following immunosuppressive therapy comprising oral immunosuppressants, steroids and biological therapy. TST requires an intradermal infiltration of T-specific cells through the induction of several cytokines, levels of which is often reduced by immunosuppressive therapy. In addition, one meta-analysis has shown a pronounced negative effect of immunosuppressive therapy on IGRA results; IGRA may not be reliable for the diagnosis of LTBI in patients undergoing immunosuppressive therapy, including TNF inhibitor, steroids, and oral immunosuppressants. Recently, Edwards et al. have evidently shown that corticosteroids significantly impair QFT-GIT performance. Since the 7 patients who developed active tuberculosis were being treated with immunosuppressive agents such as steroids at the time of LTBI test, the test results may have been affected by these agents. It should also be noted that the immune system is responsible for both yielding a positive IGRA result as well as preventing progression to active tuberculosis; as such, individuals with false-negative IGRA may be the very individuals (e.g., highly immunosuppressed) at the greatest risk of reactivation. To avoid a high rate of false-negative results, Taxonera et al. have suggested in patients with IBD that LTBI be detected through an early screening test performed in the absence of immunosuppressive treatment and/or significant inflammatory activity in order to maximize the sensitivity of the test.

A correct interpretation of the present results must be made in the light of the study's limitations. First, this was a retrospective non-randomized study conducted in a single-tertiary referral center in Korea, which is known to have an intermediate tuberculosis burden. Therefore, our results cannot be readily extrapolated to the general population of patients with IBD in other regions where the incidence rates of tuberculosis are different from ours. Second, adherence to treatment was not confirmed by direct observations, implying that noncompliance to LTBI treatment, which is difficult to ascertain, may have affected the efficacy of LTBI treatment. Third, the retrospective nature of the study may have limited the collection of accurate data regarding the close contact with active tuberculosis patients. In addition, the risk of tuberculosis can be different depending on the type of a TNF inhibitor; therefore, the result of our study may not be applied in institutions where different kinds of TNF inhibitors are frequently prescribed.

In conclusion, we showed that patients with IBD who are undergoing TNF inhibitor treatment showed a higher 1-year incidence of tuberculosis than the general population even after undergoing LTBI screening and receiving appropriate treatment. The most relevant finding was that the incidence of tuberculosis was independent of LTBI status, that is, IBD patients with or without LTBI showed a nearly similar high incidence of active tuberculosis after the initiation of TNF inhibitor treatment. These results imply that clinicians should be aware of the risk of the development of active tuberculosis in patients with IBD with negative LTBI result as well as those who receive adequate LTBI treatment following a positive result. Therefore, the careful monitoring of tuberculosis-suggestive symptoms within 1 year of TNF inhibitor therapy is imperative in patients with IBD regardless of their LTBI status and treatment.
REFERENCES

1. Chung KB, Lee EY, Im JP, Han SK, Yim JJ. Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor. *Korean J Intern Med* 2013;28(2):174-9.

2. Shim TS. Diagnosis and treatment of latent tuberculosis infection due to initiation of anti-TNF therapy. *Tuberc Respir Dis (Seoul)* 2014;76(6):261-8.

3. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing *Mycobacterium tuberculosis* infection and disease in patients due to start anti-TNF-alpha treatment. *Thorax* 2005;60(10):800-5.

4. Rampton DS. Preventing TB in patients with Crohn’s disease needing infliximab or other anti-TNF therapy. *Gut* 2005;54(10):1360-2.

5. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. *Arthritis Rheum* 2005;52(6):1766-72.

6. Lee EH, Kang YA, Lee MK, Kim YS, Kim SK, et al. Active tuberculosis incidence and characteristics in patients treated with tumor necrosis factor antagonists according to latent tuberculosis infection. *Sci Rep* 2017;7(1):6473.

7. Byun JM, Lee CK, Rhee SY, Kim HJ, Kim JW, Shim JJ, et al. The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers. *J Korean Med Sci* 2015;30(2):173-9.

8. Lee JW, Choi CH, Park JW, Kang SB, Koo JS, et al. Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. *Intest Res* 2016;14(2):146-51.

9. Jung YI, Lee JY, Jo KW, Yoo B, Lee CK, Kim YG, et al. The ‘either test positive’ strategy for latent tuberculosis infection before anti-tumour necrosis factor treatment. *Int J Tuberc Lung Dis* 2014;18(4):428-34.

10. Kim JH, Yim JJ. Achievements in and challenges of tuberculosis control in South Korea. *Emerg Infect Dis* 2015;21(11):1913-20.

11. Lee SH. Diagnosis and treatment of latent tuberculosis infection. *Tuberc Respir Dis (Seoul)* 2015;78(2):56-63.

12. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. *Am J Respir Crit Care Med* 2004;170(1):59-64.

13. Park SJ, Jo KW, Yoo B, Lee CK, Kim YG, Yang SK, et al. Comparison of LTBI treatment regimens for patients receiving anti-tumour necrosis factor therapy. *Int J Tuberc Lung Dis* 2015;19(3):342-8.

14. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. *Rheumatology (Oxford)* 2011;50(1):124-31.

15. Scrivo R, Armignacco O. Tuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data. *Int J Rheum Dis* 2014;17(7):716-24.

16. Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis in Korea 2014. http://tbzero.cdc.go.kr/tbzero/main.do. Updated 2015. Accessed October 30, 2017.

17. St-Pierre J, Chadee K. How the discovery of TNF-α has advanced gastrointestinal diseases and treatment regimes. *Dig Dis Sci* 2014;59(4):712-5.
18. Mañosa M, Domènech E, Cabrè E. Current incidence of active tuberculosis in IBD patients treated with anti-TNF agents: still room for improvement. *J Crohns Colitis* 2013;7(10):e499-500.

19. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schweiterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N Engl J Med* 2001;345(15):1098-104.

20. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. *Arthritis Rheum* 2005;52(7):1986-92.

21. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. Biphase emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay. *Ann Rheum Dis* 2012;71(2):231-7.

22. Lee SK, Kim SY, Kim EY, Jung JY, Park MS, Kim YS, et al. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea. *Lung* 2013;191(5):565-71.

23. Sichletidis L, Settas L, Spyropoulos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. *Int J Tuberc Lung Dis* 2006;10(10):1127-32.

24. Parra Ruiz J, Ortego Centeno N, Raya Alvarez E. Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. *J Rheumatol* 2003;30(7):1657-8.

25. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. *Rheumatology (Oxford)* 2005;44(6):714-20.

26. Erkens CG, Slump E, Verhagen M, Schimmel H, de Vries G, Cobelens F, et al. Monitoring latent tuberculosis infection diagnosis and management in the Netherlands. *Eur Respir J* 2016;47(5):1492-501.

27. Debeuckelaere C, De Munter P, Van Bleyenbergh P, De Wever W, Van Assche G, Rutgeerts P, et al. Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening. *J Crohns Colitis* 2014;8(6):550-7.

28. Goletti D, Sanduzzi A, Delogu G. Performance of the tuberculin skin test and interferon-γ release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. *J Rheumatol Suppl* 2014;91:24-31.

29. Wong SH, Gao Q, Tsoi KK, Wu WK, Tam LS, Lee N, et al. Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. *Thorax* 2016;71(1):64-72.

30. Edwards A, Gao Y, Allan RN, Ball D, de Graaf H, Coelho T, et al. Corticosteroids and infliximab impair the performance of interferon-γ release assays used for diagnosis of latent tuberculosis. *Thorax* 2017;72(10):946-9.

31. Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, et al. Gamma interferon release assays for detection of *Mycobacterium tuberculosis* infection. *Clin Microbiol Rev* 2014;27(1):3-20.

32. Taxonera C, Ponferrada Á, Bermejo F, Riestra S, Saro C, Martin-Arranz MD, et al. Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory bowel disease. *J Crohns Colitis* 2017;11(7):792-800.

33. Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. *J Rheumatol Suppl* 2014;91:47-55.

https://doi.org/10.3346/jkms.2018.33.e292